Back to Subject Index | Return to Arthritis & Rheumatism Table of Contents Page

• Quartz/metal dust exposure, and risk of SSc, 1306

R

• Rabbit models
  • apoptosis in experimental OA, nitric oxide and, 1266
  • interleukin-1 blockade, 515
  • methylprednisolone in osteonecrosis, 1709
  • transdermal photodynamic therapy in antigen-induced arthritis, 525
• Radiographic progression, in RA, 1470, 1571, 1583, 1867
• Rat models
  • dimethylheptyl-THC-11 oic acid (DMH-11C), antiinflammatory activity of, 163
  • macrophage migration inhibitory factor in adjuvant arthritis, 910
  • methotrexate-treated adjuvant arthritis, 1407
  • new non-MHC locus and collagen-induced arthritis, 2122
  • serum cartilage oligomeric matrix protein in chronic erosive arthritis, 544
• Raynaud's phenomenon, secondary to SSc, oral iloprost in, 670
• Reactive arthritis (ReA)
  • bacterial DNA detection by 16S rRNA-PCR in, 535
  • Chlamydia trachomatis in, 845, 1894
  • HLA associations in poststreptococcal, 1096
  • prevalence in United States, 778
  • Yersinia enterocolitica-triggered, 315, 855
• Refractory myositis, cytotoxic treatments for, 392
• Rheumatoid arthritis (RA)
  • adhesion molecules at synovial level in, 185, 2221
  • age and depressive symptoms in, 298
  • angiogenesis in, 951
  • anti-tumor necrosis factor α in, 564
  • apolipoprotein E4 in, with amyloidosis, 1328
  • apoptosis in, 1, 1251
  • arthroplasty, total joint, in, 1072
  • biologic agent combination therapy in, 1548
  • bone marrow transplantation in, 453
  • calcium-stimulated release of prostaglandin E2 in, 246
  • CCR5 chemokine receptor in, 1135
  • CD68, 306
  • CD4 in, 92, 1669, 1906, 2108
  • CD8 in, 92, 498
  • CD28 in, 2108
  • CD45RO in, 92
  • chronic myeloid leukemia in, 453
  • clinical and radiologic outcomes in DMARD-treated and -untreated, 1190
  • clinical trials and threshold for improvement in, 1564
  • clonally expanded Vα12+,CD8+ in, 498
  • cyclooxygenase 2 and safety and efficacy of inhibitor SC-58635, 1591
  • cyclooxygenase isoforms in, 122
  • cyclosporin A treatment risks in, 1930
  • cyclosporine and MTX therapy in, 1703
  • cytokines in, 48, 306, 1258, 1669
  • cytotoxicity, in extraarticular, 2108
  • depression and long-term risk for pain, fatigue, and disability in, 1851
  • diarrhea, Clostridium difficile-associated, in, 2083
  • Fas/Fas ligand in, 657
  • fatigue in, subjective predictors of, 2230
  • gene identification in synoviocytes in, 1356
  • genetic regulation of pristane-induced, in mice, 2022
  • glucocorticoids and joint tissue metabolism in early, 1203
  • HLA-B60, 498
  • HLA-Cw3 in, 498
  • HLA-DMA and -DMB in, 946, 947
  • hprt mutant T cells in, 1772
  • immunoreceptor repertoire formation for antigens in, 1911
  • immunoregulation of inflammation by interleukin-11 in, 1388
  • interferon-β in, with multiple sclerosis, 754
  • interferon-γ in, 48, 169, 307
  • interleukin-1 in, 200, 246, 1258
  • interleukin-2 in, 48, 1669
  • interleukin-4 in, 48
  • interleukin-10 in, 1669
  • interleukin-13 in, 1669
  • interleukin-12 in synovial tissue in, 306
  • interleukin-1 receptor antagonist treatment of, 2196
  • IR501 vaccine in, 1919
  • jun D transfection modulation of synovial cell function in, 470
  • keratan sulfate, cartilage proteoglycan G1 domain, inhibition in, 1019
  • limited cutaneous SSc overlap and, 1938
  • matrix metalloproteinases in, 470, 1378, 1987
  • monoclonal expansion of synoviocytes in, 1979
  • MRI in knee synovitis in, 694
  • MTX and anti-tumor necrosis factor α infusions in, 1552
  • MTX and biotechnology in, 1548
  • MTX and cyclosporine therapy in, 1703
  • MTX immunoregulation in, 48
  • mycoplasma infection in, 754, 756
  • neuropathy in, subclinical peripheral, 1196
  • NO overexpression in, induced by anti-tumor necrosis factor α monoclonal antibody, 2205
  • oral collagen in the treatment of, 191, 291
  • periodontal health in, 2081
  • phenotype, sex variations in, 817
  • in Pima Indians, 1464
  • prevalence in United States, 778
  • radiographic progression in, 1470, 1571, 1867
  • radiographic scoring of, 1583
  • response criteria validation in, 1845
  • rheumatoid nodules, cytokine and cell adhesion molecule expression in, 1783
  • robust-reaction type, 1131
  • smoking and, 184
  • synovial antigen, recognition by CD4+, CD8[minus] T cell clones, 92
  • synovial fluid, rheumatoid factor-producing B cells in, 2211
  • synovial mast cells in, CD88 on, 233
  • synovial tissue in, measuring inflammation in, 663
  • synovitis, heparan sulfate proteoglycan in, 1365
  • synovitis preceding, 1481
  • T cell receptor in, 1906, 1911
  • T cell receptor peptide vaccine in, 1919
  • thiopurine methyltransferase and azathioprine toxicity in, 1858
  • total lymphoid irradiation in, 945, 946, 947
  • tumor necrosis factor α in, 1258, 1388, 2004
• Rheumatoid Arthritis (Harris), book review, 190
• Rheumatoid arthritis-systemic sclerosis syndrome, HLA phenotype and, 757, 758
• Rheumatoid burst fractures, 747
• Rheumatologists, laboratory testing by, 725
• Rheumatology acronyms, 1901
• Ribosomal PO fusion protein, recombinant, association between serum IgG antibodies and, in lupus, 745
• Rifampicin, in oligoarthritis associated with acne and pustulosis, 1889
• Ro 32-3555 collagenase inhibitor in murine OA, 1639
• Ro/SSA and La/SSB antibodies, 927, 1625, 2238
• Roxithromycin, in oligoarthritis associated with acne and pustulosis, 1889